U.S. ITC Investigates Monster Energy Drink Imports Amid Trademark Dispute
The U.S. International Trade Commission (USITC) has launched an investigation into the alleged gray-market imports of Monster Energy drinks. This investigation follows a complaint filed by Monster on April 17, 2026, and further supplemented on May 21. Monster Energy claims that these imported products differ significantly in packaging, ingredients, and labeling, potentially infringing upon the company's U.S. trademarks.
Monster Energy is seeking a General Exclusion Order and cease-and-desist orders against several U.S. and international entities. The complaint falls under Section 337 of the Tariff Act of 1930, which addresses unfair practices in import trade. If successful, the case could establish a precedent for how companies utilize trade law to prevent unauthorized imports of their products intended for foreign markets.
According to industry experts, the outcome of this case may have broader implications for the consumer packaged goods (CPG) industry, particularly concerning trademark rights and regulatory compliance. The investigation underscores the challenges companies face in protecting their brands in a globalized market.
In related developments, Monteloeder, a company owned by SuanNutra, has received regulatory approval for its RelaxPLX sleep support ingredient in South Korea. This approval positions Monteloeder to address market gaps with science-backed, non-melatonin alternatives. The company's collaboration with COSMAX BIO facilitated efficient regulatory approval, and Monteloeder plans to expand the reach of RelaxPLX within South Korea and the broader APAC region.
Monteloeder's Commercial Director for APAC, Tomás Muñoz Gutiérrez, highlighted the growing consumer demand for sleep-support products with clinical evidence specifically linked to sleep quality. He noted the increasing interest in non-melatonin alternatives suitable for daily wellness routines, as well as innovation in product formats such as gummies, powders, and beverages.
Additionally, an Israeli health-tech startup, MeNow, is exploring the potential of AI to discover functional ingredients from industry waste streams. By analyzing the molecular makeup of botanicals, the startup has developed a library of over 60,000 organisms and 2 million natural molecules. This initiative aims to accelerate the development of safe and effective botanical supplements.
MeNow's business model includes co-development, licensing, and joint go-to-market partnerships for novel, IP-protected ingredients. One notable collaboration with Colgate resulted in identifying an optimal plant combination for treating gingivitis, significantly reducing the development time required.
